(Q35800455)

10 August 2017

Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group (English)

1 reference

10 August 2017

phase II clinical trial

0 references

Canada

0 references

author name string

Sarah Kirby

1

1 reference

10 August 2017

Stan Z Gertler

2

1 reference

10 August 2017

Warren Mason

3

1 reference

10 August 2017

Christopher Watling

4

1 reference

10 August 2017

Peter Forsyth

5

1 reference

10 August 2017

Jacinta Aniagolu

6

1 reference

10 August 2017

Robert Stagg

7

1 reference

10 August 2017

Matthew Wright

8

1 reference

10 August 2017

Jean Powers

9

1 reference

10 August 2017

Elizabeth A Eisenhauer

10

1 reference

10 August 2017

1 April 2005

1 reference

10 August 2017

1 reference

10 August 2017

7

1 reference

10 August 2017

2

1 reference

10 August 2017

183-188

1 reference

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

Chemotherapy for high-grade glioma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

The role of beta-tubulin isotypes in resistance to antimitotic drugs

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

Aberrant localization of the neuronal class III beta-tubulin in astrocytomas

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

Response criteria for phase II studies of supratentorial malignant glioma

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871890

One-sample multiple testing procedure for phase II clinical trials

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15831236

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1215/S1152851704000602

1 reference

10 August 2017

1 reference

10 August 2017

1 reference